Nemesis Bioscience Company
Novel antibiotics. Nemesis Bioscience is a new biopharmaceutical company developing Nemesis Symbiotics© - DNA therapeutics administered before antibiotics to inactivate resistance in bacterial pathogens.
Technology:
AgeTech Companies
Industry:
Covid-19
Headquarters:
United Kingdom
Employees Number:
1-10
Funding Status:
Seed
Estimated Revenue:
$1M to $10M
Register and Claim Ownership